The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) has received 8 analyst ratings in the last quarter, with 6 being bullish or somewhat bullish, and 2 being indifferent. The average price target is $89.5, significantly higher than the current price of $42.645. This target has increased by 7.83% over the past month.
August 04, 2023 | 9:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx Pharmaceutical has received positive analyst ratings, with a price target significantly higher than the current price. This could potentially drive the stock price up in the short term.
Analyst ratings are a significant factor in influencing investor sentiment and stock price. The positive ratings and high price target for Ultragenyx Pharmaceutical indicate a bullish outlook, which could potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100